Drug Profile

JZP 815

Alternative Names: JZP-815

Latest Information Update: 13 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Redx Pharma
Developer Jazz Pharmaceuticals Inc
Class Antineoplastics; Small molecules
Mechanism of Action Raf kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours
Preclinical Haematological malignancies

Most Recent Events

13 Mar 2023 Jazz pharmaceuticals has patent protection for compositions and methods of using JZP 815 in US and other countries.
16 Nov 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second line therapy or greater) in USA (PO) (NCT05557045)
15 Jun 2022 Clearance of the IND application by the US FDA triggers milestone payment from Jazz Pharmaceuticals Inc to Redx Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com